Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.60 |
| ▸ | CTSS | P25774 | 8/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18082612 | 1.00 | CTSK (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18130977 | 1.00 | CTSK (0.60) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17306038 | 0.94 | CTSK (0.62) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17306028 | 0.94 | CTSK (0.62) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17369162 | 0.91 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17449759 | 0.91 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16379313 | 0.91 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29508370 | 0.90 | CTSK (0.65) | CTSKCTSSCA1CA2 | |
| SCHEMBL245704 | 0.90 | CTSK (0.65) | CTSKCTSSCA1CA2 | |
| SCHEMBL8137516 | 0.90 | CTSK (0.65) | CTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022078487-A1 | ZOLINOSE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-04-21 | — | — | WO | claimed |
| CN-103820416-B | High-stereoselectivity esterolytic enzyme, encoding gene and application of encoding gene | 浙江工业大学 | 2017-04-12 | — | — | CN | claimed |
| WO-2022078487-A1 | ZOLINOSE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-04-21 | — | — | WO | disclosed |
| CN-111295368-A | Chemically activated water soluble prodrugs | 大日本住友制药株式会社 | 2020-06-16 | — | — | CN | disclosed |
| US-20180273553-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10011616-B2 | Boron-containing small molecules as antiprotozoal1 agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20180072760-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOALl AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-03-15 | — | — | US | disclosed |
| EP-3280717-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2018-02-14 | — | — | EP | disclosed |
| CN-103820416-B | High-stereoselectivity esterolytic enzyme, encoding gene and application of encoding gene | 浙江工业大学 | 2017-04-12 | — | — | CN | disclosed |
| WO-2016164814-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-8815932-B2 | Induction of alpha helix conformations in proteins and peptides | UNIVERSITÄT ZU KÖLN (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120172402-A1 | INDUCTION OF ALPHA HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2012-07-05 | — | — | US | disclosed |
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011616-B2 | Boron-containing small molecules as antiprotozoal1 agents | HBS1L, DBNL, BOD1L1 | CTSK 2456/4885CTSS 1183/4885CYP1A2 3110/4885 |
| US-20180072760-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOALl AGENTS | ABCB11, ABCB7, BRI3BP | CTSK 2652/4885CTSS 1233/4885CYP1A2 2724/4885 |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | CTSK 638/4885CTSS 737/4885CYP1A2 1812/4885 |
| US-20180273553-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CTSK 2368/4885CTSS 1086/4885CYP1A2 4125/4885 |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | NPY1R, PARK7, IAPP | CTSK 1393/4885CTSS 2930/4885CYP1A2 1674/4885 |
| US-20120172402-A1 | INDUCTION OF ALPHA HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES | MRPL21, CRYAA, CRYAB | CTSK 2374/4885CTSS 2984/4885CYP1A2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.